The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
The drug is being developed at lab scale for the first-line of treatment of Covid-19
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
The agreement will sharpen Cigna's focus on the growth path for its rapidly expanding global health portfolio
The aim is to first produce Covid-19 vaccines and then add more vaccines in the years to come
A growing number of studies have shown the benefit of a third dose of Covid-19 vaccine in immunocompromised subjects
Subscribe To Our Newsletter & Stay Updated
